OBJECTIVE: The goal of this study was to generate and report standardized growth curves for weight, height, head circumference, and BMI for non-growth hormone-treated white male and female US subjects with Prader-Willi syndrome (PWS) between 3 and 18 years of age and develop standardized growth charts.
WHAT'S KNOWN ON THIS SUBJECT: Syndromespecific standardized growth curves are not currently available for non-growth hormonetreated subjects with Prader-Willi syndrome and are required for monitoring growth and development in this rare obesity-related disorder.
WHAT THIS STUDY ADDS: Standardized growth curves were useful in monitoring growth and development in these subjects with Prader-Willi syndrome and for the management of growth hormone treatment of both genders, particularly those aged 3 to 18 years.
Prader-Willi syndrome (PWS) is a classic genetic disorder characterized by central hypotonia with a poor suck and feeding difficulties that is found in infancy and accompanied by failure to thrive, hypogenitalism/hypogonadism, and growth hormone deficiency. In early childhood, hyperphagia develops, which leads to obesity if left uncontrolled. Additional findings include an IQ of 65 and behavioral problems (eg, rigidity, compulsions, temper tantrums, self-injury), as well as hypopigmentation, small hands and feet, short stature, and a characteristic facial appearance. [1] [2] [3] [4] PWS occurs in ∼1 in 15 000 live births and is estimated to affect ∼400 000 people worldwide. It is considered the most common syndromic cause of life-threatening obesity 1 and arises sporadically in most cases. It is caused by loss of paternally expressed genes in the chromosome 15q11-q13 region, usually due to a deletion in ∼70% of affected subjects. [1] [2] [3] [4] Approximately 25% of cases have maternal disomy 15 or both 15s from the mother, with the remaining 5% resulting from a defect in the imprinting center controlling the activity of genes in this chromosome region. Life span in PWS is highly variable worldwide depending on the quality of medical and social care, but it is expected to be shortened due to diseaseassociated physical and neurologic problems. The chance of recurrence is low for deletion and maternal disomy subtypes (,1%), but those with an imprinting center defect may have a recurrence risk as high as 50%. 2, 4 Classically, 2 distinct stages of clinical course development have been reported in PWS: the first stage is characterized by profound hypotonia and failure to thrive in infancy and the second stage is characterized by onset of hyperphagia and subsequent obesity in early childhood with food foraging and behavioral problems. Recently, a multicenter study identified 7 different nutritional phases and subphases. The first phase describes the PWS infant with hypotonia with or without failure to thrive (age birth to 15 months); phase 2 is associated with weight gain without a significant change in appetite but followed by weight gain with an increased interest in food (median age of onset: 4.5 years); phase 3 is characterized by hyperphagia, food seeking, and lack of satiety (median age of onset: 8 years); and phase 4 indicates that an insatiable appetite may no longer exist and occurs in some adults with this obesity-related disorder. 5 Growth hormone therapy is now frequently prescribed, often in early infancy or by early childhood once the diagnosis of PWS has been confirmed. Growth hormone treatment can lead to improved changes in body composition, physical activity, and growth velocity. Because there are syndrome-specific standardized growth charts, our goal was to provide new growth charts of weight, height, head circumference, and BMI for nongrowth hormone-treated subjects with PWS between 3 and 18 years of age that can be used in the clinical setting and be helpful in monitoring growth hormone treatment in PWS. These standardized charts would replace the PWS growth charts reported by Butler and Meaney in 1991 6 of selected anthropometric measurements from subjects aged 2 to 22 years from an earlier era. Our charts are similar to the standardized growth charts recently developed for non-growth hormone-treated PWS infants between age 0 and 3 years. 7, 8 
METHODS

Subjects
Growth data were collected from 120 PWS subjects (63 males, 57 females) with genetic confirmation of PWS and no current or previous growth hormone treatment. The data were collected following standardized protocols and using an investigatorapproved manual of operation. The majority of subjects were recruited from 2003 to 2013 as a component of a large rare disease consortium on PWS research at sites representing 4 states (Florida, Tennessee, Kansas, and California). The subjects were prospectively and consecutively enrolled after genetic confirmation, often from those followed up previously in the clinical setting. Seventy-six (63%) subjects with PWS had a 15q11-q13 deletion, 42 (35%) had maternal disomy 15, and 2 (2%) had an imprinting defect. The genetic testing included chromosome analysis with fluorescence in situ hybridization, chromosome 15 methylation-specific multiplex ligation-dependent probe amplification copy number and methylation testing, genotyping with polymorphic chromosome 15 markers of proband and parental DNA, and/or chromosomal microarray studies. The inclusion criteria required genetic confirmation of PWS for each subject before growth data were used for the growth chart development; the only exclusion criteria were current or previous growth hormone treatment. All PWS participants were cared for by clinicians, geneticists, and dietitians following medical management recommendations 2 and with expertise treating subjects with PWS. Calorie-restricted diets at 60% to 80% of normal for age and activity were followed, and exercise plans (eg, 30 minutes of walking per day) were established for each participant depending on his or her age and obesity status. 2, 5, 9 Ten subjects had repeated measurements for weight, height, and/or head circumference (7 subjects with 2 measurements; 3 subjects with 3 measurements), which produced a total of 133 data points distributed from 3 to 18 years of age. Approximately 56% of the data were available from 3 to 10 years; 25% from 10 to 15 years; and 19% from 15 to 18 years of age. For comparison purposes, the 3 normative percentile curves (third, 50th, and 97th) for each growth chart were plotted from data of normal control subjects from the Centers for Disease Control and Prevention (www.cdc.gov/growthcharts/ percentile_data_files.htm) 10 for height, weight, and BMI and from Nellhaus 11 for head circumference.
Methods and Measurements
The subjects' anthropometric measurements were obtained by the authors according to standard techniques and following established protocols. 6, 10, 12 The measurements consisted of weight, height, and head circumference. Height was measured to the nearest 0.1 cm in a standing position with a sliding stadiometer fixed to the wall. Head (occipitalfrontal) circumference was measured to the nearest millimeter with a steel tape. Weight was recorded to the nearest 0.01 kg with a calibrated balanced beam or electronic digital scale.
Growth reference charts are widely used to observe or track an individual's clinical measurements in the context of population values. Growth charts for weight, height, head circumference, and BMI were developed for each gender by using the LMS method 13, 14 as used previously in the development and reporting of standardized growth curves. 7 The LMS method is a standard technique for constructing age-related growth references and summarizes the distribution of an anthropometric variable Y at each value of a covariate (age) in terms of 3 parameters: Box-Cox power l (L), median m (M), and coefficient of variation s (S):
The outcome is SD or z scores having a symmetric and nearly standard normal distribution. The optimal value of Box-Cox power to transform the data into near-normality is estimated over the range of age, and its trend is summarized by an L curve. Similarly, the estimated medians and coefficients of variation are summarized by M and S curves over the age range, respectively. Penalized likelihood estimation finds the L, M, and S curves as cubic smoothing splines, 15 with normative 97th to 50th percentiles in dark shading and 50th to third percentiles in light shading.
FIGURE 4
Standardized curves for BMI weight of non-growth-hormone treated subjects (male subjects [upper] and female subjects [lower]) with PWS (solid lines) and normative percentile ranges (shaded area) with normative 97th to 50th percentiles in dark shading and 50th to third percentiles in light shading. 1,3,1) , the normative 97th percentile was comparable to the 25th percentile for PWS from 6 to 18 years of age; however, at age 3 years, the normative third percentile was comparable to the 25th percentile for PWS, indicating the failure-to-thrive pattern of development seen in PWS at an early age. For BMI in female subjects (edf = 1,3,1), the normative 50th percentile ranged between the third (at 18 years) and the 10th (at 5 years) percentiles for PWS from age 5 to 18 years, again indicating the hyperphagia and increased weight gain, which are common in early childhood and beyond in PWS if caloric intake is not controlled. The normative 97th percentile ranged between the 25th and 50th percentiles in PWS throughout the age range from 3 to 18 years.
DISCUSSION
All PWS participants were white, with no current or previous growth hormone treatment. They were recruited in clinics from 4 states specializing in the diagnosis, treatment, and care of subjects with this rare disorder. Standardized growth curves for height, weight, head circumference, and BMI were generated from non-growth hormone-treated male and female subjects with a genetically confirmed diagnosis of PWS between 3 and 18 years of age and from healthy control subjects from the literature or databases. A deceleration of linear growth in PWS was documented specifically at the age of normal puberty relative to normative data by examining the standardized height curves in non-growth hormonetreated subjects. Although our PWS growth data were primarily crosssectional in nature, with 133 data points from 120 PWS participants, an exaggerated increase in weight gain with age was seen in both PWS male and female subjects compared with normative data indicative of this obesity-related disorder. Weight and BMI data used to develop standardized curves can be affected by the level of physical activity and degree of monitoring of caloric intake, which may vary per individual (ie, some subjects are more motivated to lose and maintain weight loss and can vary from year to year). No significant differences have been reported in male or female subjects with PWS and the typical 15q11-q13 deletion or those with the nondeletion status (ie, maternal disomy 15 or a defect of the imprinting center controlling the activity of imprinted genes). Our PWS participants do not necessarily reflect the natural history in this syndrome because our health care program at the recruitment sites included restricted caloric intake and planned physical activity to control weight.
No subject had a current or history of growth hormone use, but other factors could affect growth measures in addition to diet and energy expenditure, including sex steroid use, endocrine disturbances (eg, thyroid, pancreas, adrenal), and medications (eg, atypical antipsychotic agents). All subjects with PWS in our study were young (age range: 3-18 years), and the use of sex steroids was infrequent (,10% of subjects) and few were prescribed atypical antipsychotics. In addition, ,20% of subjects had a history of diabetes mellitus and ,10% were treated for thyroid or adrenal gland problems, reflecting reported frequencies in the PWS population. 2, 19 Recently, Butler et al 20 reported that the growth hormone receptor gene (GHR) in US children with PWS with the common exon 3 deletion polymorphism correlated with advanced height acceleration (similar to children without PWS also receiving growth hormone) compared with those without the GHR gene polymorphism. These observations should be more extensively studied in additional patients and be monitored for clinical outcomes. Growth hormone treatment that leads to improvement in stature, body composition, and metabolism from infancy through young adulthood in PWS [21] [22] [23] [24] [25] stresses the need for syndrome-specific standardized growth charts for use in monitoring longitudinal growth patterns and response to nutritional and hormone intervention.
Anthropometric or growth standards have been generated for several syndromes and used in the clinical setting for medical management. Specifically, the standardized growth charts developed for infants (0-3 years of age) with PWS are currently in use for monitoring growth parameters and development in this rare genetic obesity-related disorder. Other published growth charts for PWS have been generated. For example, Butler et al 6 The increased rate of growth in height noted during normal puberty is absent in both male and female subjects with PWS when comparing the standardized data, and this finding can best be explained by the hypogonadism common in PWS. 2 Other abnormal physical parameters in addition to height and weight are recognized in PWS, particularly skinfold measurements and hand and foot size. [27] [28] [29] The abnormal parameters in PWS can be appreciated earlier after comparing data with syndrome-specific standardized growth curves. Medical care in PWS and other genetic syndromes (ie, Down syndrome, Turner syndrome) has become increasingly reliant on growth charts (normal and syndrome specific) to compare growth patterns at an early age due to better diagnostic techniques, more awareness, and availability of hormone replacement (eg, growth hormone).
CONCLUSIONS
Growth charts help optimize medical care and treatment in subjects with rare disorders such as PWS who have impaired growth (short stature secondary to growth hormone deficiency) and complicated further by failure to thrive and feeding difficulties in infancy. The onset of hyperphagia in PWS usually occurs in early childhood and leads to rapid weight gain and subsequent obesity, as illustrated by distortions observed in the newly developed growth patterns relative to normative data. Diagnosis is needed at an early age, with caloric restriction and increased physical activity to avoid the onset of obesity and medical comorbidities. Fortunately, better awareness now exists in the medical community, and more appropriate genetic testing methods are available for an early diagnosis and treatment with growth hormone for affected individuals with PWS. With early diagnosis and treatment, the quality of life and clinical outcome in PWS have improved with support of standardized growth curves used by the clinician and dietitian in the care of infants with PWS. However, those health care providers regularly supplying medical care for PWS subjects recognize the need for current standardized growth charts between 3 and 18 years of age to monitor nutrition, growth rate, and obesity. In addition, standardized growth charts can be used to guide growth hormone therapy and monitor for accelerated growth rate, orthopedic problems such as scoliosis, or other clinical features seen in this rare obesity-related genetic disorder. To meet those needs, if they should arise, the authors encourage the use of these newly established syndromespecific standardized growth charts in the clinic setting for the medical care and treatment of subjects with PWS.
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